Denali Therapeutics Stock Equity Positions Weight
| DNLI Stock | USD 21.45 0.04 0.19% |
Denali Therapeutics fundamentals help investors to digest information that contributes to Denali Therapeutics' financial success or failures. It also enables traders to predict the movement of Denali Stock. The fundamental analysis module provides a way to measure Denali Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Denali Therapeutics stock.
Denali | Equity Positions Weight |
Denali Therapeutics Company Equity Positions Weight Analysis
Denali Therapeutics' Percentage of fund asset invested in equity instruments. About 80% of global funds and ETFs carry equity instruments on their balance sheet.
More About Equity Positions Weight | All Equity Analysis
Stock Percentage | = | % of Equities | in the fund |
Denali Equity Positions Weight Driver Correlations
Understanding the fundamental principles of building solid financial models for Denali Therapeutics is extremely important. It helps to project a fair market value of Denali Stock properly, considering its historical fundamentals such as Equity Positions Weight. Since Denali Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Denali Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Denali Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Funds with most asset allocated to stocks can be subclassified into many different categories such as market capitalization or investment style.
| Competition |
According to the company disclosure, Denali Therapeutics has an Equity Positions Weight of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Denali Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Denali Therapeutics from analyzing Denali Therapeutics' financial statements. These drivers represent accounts that assess Denali Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Denali Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 1.9B | 1.7B | 9.1B | 3.5B | 2.9B | 2.2B | |
| Enterprise Value | 1.8B | 1.7B | 8.7B | 3.3B | 2.9B | 2.1B |
Denali Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Denali Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Denali Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Denali Fundamentals
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.24 | ||||
| Current Valuation | 2.31 B | ||||
| Shares Outstanding | 143.92 M | ||||
| Shares Owned By Insiders | 9.66 % | ||||
| Shares Owned By Institutions | 91.40 % | ||||
| Number Of Shares Shorted | 7.37 M | ||||
| Price To Earning | 60.91 X | ||||
| Price To Book | 2.35 X | ||||
| Price To Sales | 3,339 X | ||||
| Revenue | 330.53 M | ||||
| Gross Profit | (250.27 M) | ||||
| EBITDA | (179.97 M) | ||||
| Net Income | (145.22 M) | ||||
| Cash And Equivalents | 1.07 B | ||||
| Cash Per Share | 8.66 X | ||||
| Total Debt | 52.24 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 3.20 X | ||||
| Book Value Per Share | 9.17 X | ||||
| Cash Flow From Operations | (357.99 M) | ||||
| Short Ratio | 7.68 X | ||||
| Earnings Per Share | (2.76) X | ||||
| Target Price | 42.77 | ||||
| Number Of Employees | 390 | ||||
| Beta | 1.39 | ||||
| Market Capitalization | 3.09 B | ||||
| Total Asset | 1.15 B | ||||
| Retained Earnings | (1.12 B) | ||||
| Working Capital | 986.15 M | ||||
| Current Asset | 281.74 M | ||||
| Current Liabilities | 10.46 M | ||||
| Net Asset | 1.15 B |
About Denali Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Denali Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Denali Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Denali Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Denali Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Denali Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Denali Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Denali Therapeutics Stock:Check out Denali Therapeutics Piotroski F Score and Denali Therapeutics Altman Z Score analysis. For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Denali Therapeutics. If investors know Denali will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Denali Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.76) | Quarterly Revenue Growth (1.00) | Return On Assets (0.24) | Return On Equity (0.35) |
The market value of Denali Therapeutics is measured differently than its book value, which is the value of Denali that is recorded on the company's balance sheet. Investors also form their own opinion of Denali Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Denali Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Denali Therapeutics' market value can be influenced by many factors that don't directly affect Denali Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Denali Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Denali Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Denali Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.